Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Genscript Biotech Corporation

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

COMPLETION OF THE DISCLOSEABLE TRANSACTION IN RELATION TO THE SHARE REPURCHASES OF PROBIO CAYMAN FROM THE OFFSHORE SELLERS

Reference is made to the announcement of Genscript Biotech Corporation (the "**Company**") dated 24 November 2026 in relation to, among others, the Share Repurchases (the "**Announcement**"). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board hereby announces that all the conditions to the closings under the Share Repurchase Agreements with the Offshore Sellers have been fulfilled and the closings of the relevant Share Repurchases took place on 26 November 2026 (the "**Offshore Repurchase Completion**"). Pursuant to the relevant Share Repurchase Agreements, ProBio Cayman repurchased an aggregate of 102,857,135 Series C Preferred Shares from the Offshore Sellers for an aggregate consideration of approximately US$101.3 million. The repurchased Series C Preferred Shares will be cancelled as soon as practicable following the Offshore Repurchase Completion in accordance with the applicable requirements of the Companies Act of the Cayman Islands and the memorandum and articles of association of ProBio Cayman.

The Share Repurchases involving the Onshore Sellers have not yet been completed as at the date of this announcement, as the settlement of the consideration payable to the Onshore Sellers is subject to the obtaining of the relevant ODI Approvals. The Company will make further announcement(s) in relation to the completion of the remaining Share Repurchases as and when appropriate.

Immediately before the Offshore Repurchase Completion, the Company held, directly and indirectly, an aggregate of 2,011,774,741 shares in ProBio Cayman, representing approximately 89.68% of the issued share capital of ProBio Cayman. Immediately after the Offshore Repurchase Completion, the Company has an interest of approximately 93.99% of the issued share capital of ProBio Cayman, assuming that the shares repurchased upon the Offshore Repurchase Completion has been cancelled and none of the ESOP Shares have been allotted or issued.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 26 November 2026

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng ("**Mr. Robin Meng**"), Dr. Fangliang Zhang ("**Dr. Frank Zhang**"), Dr. Li Zhu and Ms. Ye Wang ("**Ms. Sally Wang**"); and the independent non-executive Directors are Mr. Yiu Leung Andy Cheung ("**Mr. Andy Cheung**"), Mr. Jiuan Pan ("**Mr. Ethan Pan**"), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi ("**Dr. Victor Shi**").*